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Introduction
 Simultaneous double cancers can differ in 
clinical stage and principles of treatment. It 
is necessary to determine the clinical stage 
of each cancer to accurately diagnose and 
thereby select the optimal treatment for each 
tumor. We report a case of simultaneous pri-
mary gastric cancer and bladder cancer with 
a rare mode of metastasis.
Case history
 A-60-year-old woman presented to our 
gynecology department with a chief com-
plaint of lower abdominal discomfort. She 
had undergone a muscle-preserving radical 
mastectomy for right breast cancer in 1998. 
Pathological findings were consistent with 
a scirrous carcinoma, and the pathological 
staging was pT2, pN2, pM0, stage IIIa. Post-
operative therapy was tamoxifen and doxi-
fluridine, taken orally for five years and six 
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Abstract　A 60-year-old woman presented to our hospital with lower abdominal dis-
comfort. Abdominal computed tomography showed a bladder tumor and a metastatic 
liver tumor. Gastric cancer was suspected to be the primary tumor for the hepatic 
metastasis. Biopsy of the gastric tumor revealed adenocarcinoma, biopsy of bladder 
tumor squamous cell carcinoma mixed with transitional cell carcinoma. The patient 
was admitted for gastrectomy and biopsy of the metastatic liver tumor. We per-
formed distal partial gastrectomy with D2 dissection and Billroth I reconstruction, 
with partial resection of the liver tumor in segment 3. Histopathological examination 
revealed a moderately differentiated tubular adenocarcinoma, subserosa. Metasta-
sis to the No.4d lymph node was adenocarcinoma and that to the No.8a and 9 lymph 
nodes were squamous cell carcinoma mixed with transitional cell carcinoma from the 
bladder cancer. The metastatic liver tumor was also found to be from the bladder can-
cer. The patient had an uneventful post-operative course, and was transferred from 
the surgical ward to the department of urology for chemotherapy, 14 days postop-
eratively. She ultimately died of leptomeningial carcinomatosis, 10 months after the 
operation. It is extremely rare with regional lymph node metastasis of stomach from 
mixed double gastric and bladder cancers.
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months after radiotherapy. The patient had 
undergone total abdominal hysterectomy 
and salpingo-oophorectomy for a suspected 
endometrial cancer in 2004. Pathological 
findings indicated endometrial hyperplasia. 
The genetic test was not accomplished, but 
there was not the person infected with can-
cer to the close relatives, and Li-Fraumeni 
syndrome was denied. Abdominal computed 
tomography (CT) and magnetic resonance 
imaging (MRI) showed bladder, gastric and 
metastatic liver tumors (Fig. 1A, B) and up-
per gastrointestinal fiberscopy revealed gas-
tric cancer (Fig. 2A). Tumor markers were 
elevated (CEA 5.2 ng/ml, CA19-9 186.9 U/ml, 
and SCC 98.4 ng/ml). Abdominal CT showed 
an approximately 3 cm gastric tumor in the 
lower portion of the stomach and swelling of 
the regional lymph nodes, low density areas 
in both lobes of the liver, an approximately 
5 cm in diameter tumor invading the upper 
left pelvis of the bladder with swelling of re-
gional lymph nodes, left hydronephrosis, and 
swelling of para-aortic lymph nodes. Low 
density areas in both lobes of the liver in the 
CT were diagnosed as metastatic liver tumor, 
but the breast cancer, the gastric cancer, 
any metastasis of the bladder cancer were 
unknown. Upper gastrointestinal fiberscopy 
showed an approximately 4 cm type 2 tumor 
in the lower portion of the greater curvature 
of the stomach, and biopsy of this tumor 
revealed an adenocarcinoma. Cystoscopy 
showed pressure from the left of the bladder 
wall (Fig. 2B) and that the left ureteric orifice 
was closed by the tumor. Biopsy of the blad-
der tumor revealed squamous cell carcinoma 
mixed with transitional cell carcinoma (Fig. 
3A). Bone scintigraphy showed no metasta-
ses to bone. The preoperative diagnosis was 
simultaneous primary gastric and bladder 
cancers. Chemotherapy rather than surgery 
was indicated for the bladder cancer because 
of the pelvic lymph node metastasis. A distal 
partial gastrectomy was indicated for the 
gastric cancer as a means of prophylactically 
treating bleeding and obstruction. Metastatic 
regional lymph nodes were considered to 
likely represent metastases from the gastric 
cancer. Metastases involving the para-aorta 
Fig. 1  A: Abdominal CT showing a metastatic liver tumor (↓) and gastric cancer (↓↓). 
B: Abdominal CT showing a mass approximately 5 cm in diameter in the upper 
left pelvis of the bladder (↓).
Fig. 2  A: Upper gastrointestinal fiberscopy showed an approximately 4 cm type 2 tu-
mor. B: Cystoscopy showed pressure from the left of the bladder wall.
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lymph nodes and liver were of uncertain ori-
gin, as the gastric cancer, bladder cancer and 
even the right breast cancer 11 years earlier, 
were all possible sources. We performed a 
distal partial gastrectomy with D2 dissection 
and Billroth I reconstruction for prevention 
of bleeding and obstruction, with partial 
resection of the liver tumor in segment 3 
to confirm metastasis of any cancer. Histo-
pathological examination revealed a moder-
ately differentiated tubular adenocarcinoma 
(Fig. 3B), subserosa (ss). Metastasis to the 
No. 4d lymph node (greater curvature nodes) 
was adenocarcinoma (Fig. 4A), that to the 
No. 8a lymph nodes (common hepatic artery 
nodes anterosuperior group) and No. 9 lymph 
nodes (celiac artery nodes) was squamous cell 
carcinoma mixed with transitional cell carci-
noma from the bladder cancer (Fig. 4B). The 
metastatic liver tumor was also found to be 
from the bladder cancer (Fig. 4C). We consid-
ered the clinical stage to be ss (T2), n1, stage 
Fig. 3  A: Squamous cell carcinoma (↓ ) mixed with transitional cell carcinoma was 
diagnosed by biopsy of the bladder tumor. (H.E. stain×100.) B: Pathological 
examination of the gastric cancer revealed moderately differentiated tubular 
adenocarcinoma. (H.E. stain×100.) 
Fig. 4  A: The No.4d lymph node metastasis was adenocarcinoma from the gastric can-
cer. (H.E. stain×100.) B: The No. 9 lymph node metastasis was squamous cell 
carcinoma (↓) mixed with transitional cell carcinoma from the bladder cancer. 
(H.E. stain×200.) The No.8a and No. 9 lymph node metastases had the same 
characteristics. C: The metastatic liver tumor was squamous cell carcinoma (↓) 
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II, and there was curative potential of gastric 
resection with Resection A for the gastric 
cancer. We considered the para-aortic lymph 
node swelling to represent metastasis of the 
bladder cancer. The postoperative course was 
uneventful and the patient was transferred 
from the surgical ward to the department of 
urology for chemotherapy, 14 days postop-
eratively. She received cisplatin 100 mg/body 
on day 1, and gemcitabine hydrochloride 1.6 
g/body on days 1 and 8 every 3 weeks. Three 
courses of this regimen were administered. 
Next, the patient received epirubicin hydro-
chloride 80 mg/body on day 1, methotrexate 
50 mg/body on day 1, calcium folinate 45 
mg/body on day 1 and 75 mg/body on day 2, 
and nedaplatin 60-80 mg/body on days 2 and 
3. Two courses of this regimen were admin-
istered. Abdominal CT showed a remarkable 
reduction of the primary bladder cancer and 
lymph node metastasis in the abdomen but 
the liver metastasis was unchanged. The he-
patic arterial infusion chemotherapy regimen 
was carboplatin 360-575 mg/body on day 1, 
gemcitabine hydrochloride 0.8-1 g/body on 
day 1, and docetaxel 60-80 mg/body on day 
1. Three courses of this regimen were ad-
ministered. However, abdominal CT showed 
progression of the primary bladder cancer, 
the lymph node metastases in the abdomen 
and the liver metastasis. She was admit-
ted with complaints of gait disturbance and 
dysarthrosis, 10 days after being discharged 
following the final chemotherapy. Head MRI 
showed leptomeningial carcinomatosis in the 
brain. The patient died 14 days after the final 
admission, i.e. 10 months after surgery (Fig. 
5).
Discussion
 Definitions of multiple primary malignant 
tumors have been widely applied based on 
the criteria proposed by Warren and Gates, 
i.e., that each of the tumors must present a 
definite picture of malignancy, each must be 
distinct, and the probability of one being a 
metastasis of the other must be excluded.１） 
The double cancers in our case were a gastric 
tumor found to be a moderately differenti-
ated tubular adenocarcinoma and a bladder 
cancer showing squamous cell carcinoma 
mixed with transitional cell carcinoma, and 
thus met Warren and Gateʼs criteria.
 Surgical resection of gastric cancer is a 
well established treatment. Guidelines for 
the diagnosis and treatment of carcinoma of 
the stomach include the operative method, 
Fig. 5　Clinical course and tumor marker value.
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the area of lymph node dissection, and so on, 
according to clinical stage.２） The regional 
lymph nodes of the stomach are classified 
into station numbers and into three groups, 
depending upon the location of the primary 
tumor, in the Japanese classification of gas-
tric carcinoma,３－６) and the Japanese Classifi-
cation of Gastric Carcinoma describes lymph 
node metastasis from a nearby regional 
lymph node to distant regional lymph nodes, 
that is, from an n1 lymph node to a para-aor-
tic lymph node via n2 and n3 lymph nodes. 
 Regional lymph node metastases of bladder 
cancers are not classified depending upon the 
location of the primary tumor but rather on 
the number and/or size of metastatic region-
al lymph nodes,７） based on the TNM clas-
sification of the international union against 
cancer.８） The classifications of regional 
lymph node metastasis differ between gastric 
and bladder cancers, because lymph flow as-
sociated with the bladder involves various 
lymph nodes in the pelvis. Lymph from the 
bladder drains into the internal iliac nodes, 
though some lymph from the base may pass 
directly to the internal iliac and common iliac 
nodes, and some from the neck of the bladder 
may go directly to the sacral nodes.９） Lymph 
node metastasis of bladder cancer report-
edly involves the paravesical nodes in 16%, 
the obturator nodes in 74%, the external iliac 
nodes in 65%, the presacral nodes in approxi-
mately 25%, and juxtaregional lymph nodes 
in approximately 20% of cases.10） Thus, blad-
der cancer can metastasize to several pelvic 
lymph nodes.
 Regional lymph node metastasis due to a 
mix of gastric and bladder cancers is very 
rare. An extensive literature search using 
the key words gastric cancer, bladder cancer, 
regional lymph node metastasis, metasta-
sis, and/or double cancer, from 1950 to 2010, 
yielded no reports similar to our case in 
PubMed. We speculate that the gastric cancer 
metastases had originated from the primary 
gastric tumor and reached the No.4d lymph 
nodes (greater curvature nodes) normograde-
ly, while those of the primary bladder cancer 
had reached the pelvic and para-aortic lymph 
nodes and then spread from the para-aortic 
to the No. 8a lymph nodes (common hepatic 
artery nodes anterosuperior group) and No. 9 
lymph nodes (celiac artery nodes) retrograde-
ly.
 More than 90% of bladder cancers are 
transitional cell carcinomas. Squamous cell 
carcinoma accounts for only 1% of bladder 
cancer in England, and 3% to 7% in the United 
States. Squamous cell carcinoma accounts 
for 3.2% (9/285) and squamous cell carcinoma 
mixed with transitional cell carcinoma ac-
counts for 9.1% (26/285) of bladder cancer 
in Japan.11） Friedell10） reported the rate of 
mixed tumors comprised of both squamous 
cell carcinoma and transitional cell carci-
noma to be 6.0%. Squamous cell carcinomas 
are usually caused by chronic irritation from 
urinary calculi, long-term indwelling cath-
eters, chronic urinary infections, or bladder 
diverticula.12） Conversely, squamous cell car-
cinoma accounts for as much as 75% of blad-
der cancer in Egypt, and approximately 80% 
of squamous cell carcinomas in Egypt are 
associated with chronic infection with Schis-
tosoma haematobium.12） 
 Distal metastasis from squamous cell car-
cinoma of the bladder is rare,13） with meta-
static disease being confirmed in only 8.8% of 
cases.13） Thus, squamous cell carcinoma of the 
bladder is considered to be highly invasive at 
the local level. The prognosis of squamous 
cell carcinoma of the bladder is reportedly 
poor; only 23.8% of patients were alive one 
year after the diagnosis and the 5-year sur-
vival rate was 1.9%.12） In one study, 92.2% of 
patients with squamous cell carcinoma of the 
bladder were found to have invasive tumors 
(T2-T4) at diagnosis,14） and most patients die 
after attempts at locoregional tumor control 
have failed.13） Takai reported that squamous 
cell carcinoma mixed with transitional cell 
carcinoma was the property that resembled 
transitional cell carcinoma well, and spe-
cial mention for squamous cell carcinoma 
mixed with transitional cell carcinoma was 
not accomplished.11） Charbit15） reported that 
primary squamous cell carcinoma exhibited 
a faster growth rate, followed by primary 
adenocarcinomas, and that the growth rate 
of squamous cell carcinoma was exceeded 
by the growth rate of its metastases. As 
noted above, we considered the prognosis of 
squamous cell carcinoma of the bladder to 
be poor as it shows marked local invasive-
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ness, progresses rapidly with deep invasion, 
and quickly invades distant organs, i.e., is a 
highly invasive tumor.
 For this patient, we decided to perform re-
section A (no residual disease with high prob-
ability of cure) for the gastric cancer, as the 
clinical stage was T2 (ss), n1, stage II and the 
patient underwent D2 dissection (all Group 
1 and Group 2 nodes).３） Thus, adjuvant che-
motherapy was not always necessary for the 
gastric cancer. At present, there is no recom-
mended adjuvant chemotherapy regimen for 
gastric cancer and a course of 5-FU/CDDP,16） 
UFT,17） or TS-118） is administered according to 
the standard of each institution. 
 Clinically, the bladder cancer which had 
metastasized to lymph nodes of the pelvis 
and to the liver was stage IV, an indication 
for chemotherapy but not surgery. However, 
there is no established regimen for squamous 
cell carcinoma and squamous cell carcinoma 
mixed with transitional cell carcinoma of the 
bladder, such that a regimen recommended 
for transitional cell carcinoma of the bladder 
was used. The standard regimen for advanced 
transitional cell carcinoma of the bladder, 
according to Sternberg, was methotorexate/
vinblastine/doxorubicin/cisplatin (M-VAC).19） 
Recently, however, a randomized controlled 
trial revealed gemcitabine/cisplatin (GC) to 
provide efficacy similar to that of M-VAC with 
a better safety profile and tolerability.20）21） GC 
therapy is anticipated to replace M-VAC as 
the standard treatment for advanced meta-
static bladder cancer. 
 We experienced a rare case with regional 
lymph node metastasis of stomach from 
mixed double gastric and bladder cancers. 
Thus, in cases with simultaneous double can-
cers, we must determine the stage and select 
the most appropriate therapy for each tumor 
because therapeutic regimens differ among 
cancers.
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